Simon Dai
Director at Waldecast plc and serves as Chairman and CEO of Obagi China. Prior to Waldencast, Simon was the Chairman of Obagi Global Hodling. He led several investments in the healthcare space, including Obagi (acquired from Bausch Health) and Presbia (co-invested with Orchard Capital). Previously, Simon focused on impact investing at Bill & Melinda Gates Foundation where he was a Liaison Officer based in Ethiopia. He also co-founded Oxford MEStar, a spin-out company from the Institute of Biomedical Engineering of Oxford University specializing in translational and regenerative medicine. Simon received a BA in Sociology from Manchester University. MSc. In Financing from London School of Economics, and an MBA from UCLA Anderson School of Management.